Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Lymphangioleiomyomatosis: differential diagnosis and optimal management.
[lymphangioleiomyomatosis]
Lymphangioleiomyomatosis
(
LAM
)
is
an
uncommon
disease
presented
as
diffuse
thin
-walled
cystic
changes
in
the
lung
.
The
main
differential
diagnoses
include
pulmonary
Langerhans
'
histiocytosis
(
PLCH
)
,
Birt-
Hogg-
Dubé
syndrome
(
BHD
)
,
lymphoid
interstitial
pneumonia
(
LIP
)
,
and
amyloidosis
.
A
combination
of
clinical
,
radiological
,
and
pathological
approaches
as
well
as
genetic
testing
will
clarify
the
diagnosis
in
most
cases
.
LAM
is
a
disease
almost
exclusively
in
women
.
Dyspnea
,
pneumothorax
,
and
hemoptysis
are
common
presentations
in
LAM
patients
.
LAM
is
also
a
lymphatic
disorder
affecting
lymphatic
vessels
and
lymph
nodes
.
Chylothorax
,
chylous
ascites
,
and
lymphangiomyomas
are
frequently
seen
.
LAM
can
present
sporadically
as
a
single
entity
or
as
part
of
tuberous
sclerosis
complex
(
TSC
)
.
Angiomyolipoma
(
AML
)
is
a
characteristic
extra
-
pulmonary
lesion
,
either
found
in
association
with
sporadic
or
TSC-related
LAM
.
High
-risk
populations
should
be
screened
for
LAM
,
including
adult
women
with
TSC
and
female
patients
with
spontaneous
pneumothorax
,
AMLs
in
the
kidney
,
and
diffuse
cystic
lung
diseases
.
Definitive
diagnosis
of
LAM
is
based
on
a
high
level
of
clinical
suspicion
on
presentation
supported
by
pathological
findings
or
by
a
distinct
feature
,
such
as
a
history
of
TSC
,
AMLs
in
the
kidney
,
chylothorax
,
or
chylous
ascites
.
Vascular
endothelial
growth
factor
-
D
(
VEGF-D
)
in
serum
is
a
noninvasive
and
reliable
diagnostic
biomarker
.
In
experienced
centers
,
trans-bronchial
lung
biopsy
(
TBLB
)
provides
a
convenient
and
safe
way
to
obtain
lung
specimens
for
diagnostic
purposes
.
An
effective
treatment
for
LAM
is
now
available
,
namely
using
a
mechanistic
target
of
rapamycin
(
mTOR
)
inhibitor
such
as
sirolimus
.
Efficacy
of
sirolimus
has
been
confirmed
in
clinical
trials
.
Research
in
other
molecular-targeted
therapies
is
under
investigation
.
A
previously
little-known
rare
disease
with
no
cure
is
now
better
understood
with
regards
to
its
pathogenesis
,
diagnosis
,
and
management
.
In
this
review
,
current
knowledge
in
diagnosis
and
differential
diagnosis
of
LAM
will
be
discussed
,
followed
by
the
discussion
of
therapy
with
mTOR
inhibitors
.
Diseases
Validation
Diseases presenting
"dyspnea"
symptom
acute rheumatic fever
allergic bronchopulmonary aspergillosis
carcinoma of the gallbladder
congenital diaphragmatic hernia
cushing syndrome
cutaneous mastocytosis
dedifferentiated liposarcoma
erdheim-chester disease
esophageal carcinoma
fabry disease
familial mediterranean fever
inclusion body myositis
liposarcoma
lymphangioleiomyomatosis
neuralgic amyotrophy
pleomorphic liposarcoma
primary effusion lymphoma
scrub typhus
systemic capillary leak syndrome
thoracic outlet syndrome
well-differentiated liposarcoma
This symptom has already been validated